KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Leases (2019 - 2025)

Jazz Pharmaceuticals has reported Leases over the past 14 years, most recently at $58.9 million for Q4 2025.

  • Quarterly Leases rose 9.89% to $58.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.9 million through Dec 2025, up 9.89% year-over-year, with the annual reading at $58.9 million for FY2025, 9.89% up from the prior year.
  • Leases was $58.9 million for Q4 2025 at Jazz Pharmaceuticals, down from $61.2 million in the prior quarter.
  • Over five years, Leases peaked at $149.3 million in Q2 2021 and troughed at $5.9 million in Q3 2021.
  • The 5-year median for Leases is $71.1 million (2023), against an average of $72.5 million.
  • Biggest five-year swings in Leases: tumbled 95.52% in 2021 and later skyrocketed 1159.66% in 2022.
  • Tracing JAZZ's Leases over 5 years: stood at $86.6 million in 2021, then dropped by 15.31% to $73.3 million in 2022, then fell by 10.89% to $65.3 million in 2023, then decreased by 18.0% to $53.6 million in 2024, then increased by 9.89% to $58.9 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $58.9 million, $61.2 million, and $63.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.